Remove tag company-profile
article thumbnail

Novelist John Green launches attack on Cepheid over the price of its TB test

STAT

John Green, a novelist and high-profile YouTuber, is once again leveraging his star power in the global fight to end tuberculosis. The diagnostics company Cepheid and the price of its tuberculosis test, GeneXpert. each, which lab technicians can analyze in a speedy machine that is also sold by the company. His latest target?

137
137
article thumbnail

Leading innovators in peptide nano-particle conjugates for the pharmaceutical industry

Pharmaceutical Technology

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Advanced therapies and the high-profile pricing dilemma

pharmaphorum

However, with a price tag of €1.58 million, the company could not find government and payers ready to meet the cost and chose to withdraw from the European market , rather than lower the price. However, a recently released report from the organisation could blow the price tag of Zolgensma out of the water. At more than $2.1

130
130
article thumbnail

Owkin taps Linux Foundation to open-source its AI learning software

pharmaphorum

Instead, an AI learned from each of the company’s datasets in turn, retaining no actual data but lots of aggregate impressions. A number of companies have sprung up offering AI models to help pharma companies with drug discovery over the past few years.

article thumbnail

Almirall and IRB Barcelona team up to tackle skin disease

pharmaphorum

Two Spanish pharma companies are joining forces to identify new oral treatments for immune-inflammatory skin diseases with high unmet medical needs. However, states the company, many of these potentially therapeutically relevant proteins are “not amenable to conventional small-molecule inhibitors, as they lack defined ligand-binding pockets”.

article thumbnail

bluebird bio to split into oncology and gene therapy specialists

pharmaphorum

US biotech bluebird bio has announced plans to split into two this year, with a separate oncology business spinning off as the company prepares to bring its products to market. Meanwhile the as-yet unnamed oncology company will spin off under the leadership of bluebird’s current chief executive Nick Leschly. million price tag.

FDA 60
article thumbnail

bluebird bio ‘baffled’ after NICE rejects beta-thalassaemia gene therapy

pharmaphorum

In this first draft guidance NICE raised a series of issues with Zynteglo, which bluebird has already agreed to supply at a confidential discount from its hefty price tag, which is around €1.57 She pointed out that the dossier presented to NICE was compiled in 2019 and the company now has six years’ worth of follow-up data.

72